Shorter radiation schedule after surgery for head and neck squamous cell cancer
Tests a shorter radiation schedule after surgery in adults with head and neck cancer.
Plain-language title generated from the registry record
Registry title: Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies
Key facts
- Where
- Jhajjar, IndiaSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07573956, who can take part
Where in India
- Dr. Aman Sharma, Associate Professor, Radiation Oncology, NCI, AIIMSJhajjar, IndiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- All India Institute of Medical Sciences
- Trial code
- NCT07573956
- Record updated
- 7 May 2026
- Original description
Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT for HNSCC. There is a strong radiobiological and economic rationale for delivery hypo-fractionated radiotherapy in HNSCC. The HYPCON III trial will be aimed to reduce the number of fractions by 50% (30 fr to 15 fr)Read full original descriptionShow less
The HYPCON 3 Trial A Phase II/III Randomized Study Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant Radiation Therapy in Head and Neck Malignancies
Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT for HNSCC. There is a strong radiobiological and economic rationale for delivery hypo-fractionated radiotherapy in HNSCC. The HYPCON III trial will be aimed to reduce the number of fractions by 50% (30 fr to 15 fr)
Inclusion: Patients with pT1-4 squamous cell carcinoma of oral cavity/ oropharynx/ larynx/ hypopharynx with any of the intermediate risk features:; Positive lymph node (s); Perineural invasion; Lympho-vascular invasion; Close margins; Age 18-80yrs; ECOG performance status 0-1at time of surgery; Informed consent; Available FOR long term follow-up.
Exclusion: High risk factors following resection: positive-margin(s)and/or extra nodal extension (ENE); Patients receiving Neo-adjuvant or concurrent Chemotherapy; Prior Radiotherapy to head and neck region; Synchronous or second primary malignancy outside of the oropharynx, oral cavity, larynx and hypopharynx; pT1-2disease and no high-risk features (LVSI, PNI, Close margins,pN0); Non-Squamous Histology; Distant metastasis; Pregnant females or nursing mothers due to the probability of congenital anomalies and potential of this regimen to harm nursing infants.